Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin Plus Nivolumab in Relapsed/Refractory Hodgkin Lymphoma
NCT05039073Phase 2Recruiting
- Sponsor
- Emory University
- Start
- May 2022
- Primary completion
- Nov 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin, nivolumab in classic Hodgkin lymphoma (cHL), sponsored by Emory University. Started May 2022; status: recruiting.
02
Drugs
brentuximab vedotinnivolumab
03
Conditions
classic Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT05039073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05039073.